Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Richard J. Gray et al.|Clinical Cancer Research|2017Cited by 74
The Integration of Clinical Trials With the Practice of MedicineDerek C. Angus, Alison J. Huang, Roger Lewis et al.|JAMA|2024Cited by 71
Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for EvidenceJoseph B. Franklin, Rohan Khera, Caroline Marra et al.|JAMA|2024Cited by 25
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker DiscoveryKathy S. Albain, Laura J. Esserman, Christina Yau et al.|Clinical Cancer Research|2023Cited by 20